Browse the evidence

Family involvement and structured family therapy significantly enhance postoperative weight loss, adherence, and psychosocial outcomes.

Involve your family in your postoperative care. Structured family therapy can significantly improve weight loss and psychosocial outcomes. Address any family resistance through open communication and counseling.

GLP-1 receptor agonists (e.g., semaglutide) induce significant weight loss through hormonal mechanisms but carry a high risk of psychological dependency and rebound weight gain upon discontinuation, necessitating their use as temporary adjuncts to lifestyle interventions rather than standalone long-term solutions.

If you are using GLP-1 drugs, treat them as a temporary bridge to build sustainable habits, not a permanent solution. Prioritize resistance training and protein intake to protect muscle mass, as rapid weight loss without exercise increases frailty risk. Plan for discontinuation early by integrating behavioral therapy and dietary changes to prevent rebound weight gain and dependency.

Sirona, a gastro-retentive dual-network polymer hydrogel, promotes weight loss and reduces dietary intake in adults with obesity (BMI 30-40 kg/m2) through mechanical gastric retention, demonstrating a large effect size compared to placebo in a 12-week pilot trial.

Sirona is a non-drug weight loss option for people with obesity (BMI 30-40). It works by swelling in the stomach to help you feel full, leading to reduced food intake and weight loss. In a short trial, it helped people lose about 4% of their body weight over 12 weeks, which is a significant amount. Side effects like nausea are common at first but are usually mild and go away. It requires taking pills daily with water on an empty stomach, along with basic healthy eating and exercise advice.

Tirzepatide, a dual GLP-1/GIP receptor agonist, demonstrates significant efficacy in reducing body weight (over 20% in some cases) and improving glycemic control in patients with type 2 diabetes and obesity, suggesting therapeutic potential for women with Polycystic Ovary Syndrome (PCOS) who have comorbid obesity and insulin resistance.

For women with PCOS and obesity, tirzepatide offers a promising pharmacological tool to address both metabolic and reproductive symptoms. While not yet standard care for PCOS specifically, its ability to induce significant weight loss (>20%) and improve insulin sensitivity suggests it may help restore ovulation and reduce androgen levels. Treatment involves weekly subcutaneous injections starting at 2.5mg and titrating up to 15mg, ideally combined with lifestyle changes. Patients should be aware of potential GI side effects, though the drug's design aims to mitigate them.

GLP-1 agonists (semaglutide, tirzepatide) produce significant weight loss (15-21%) but are associated with isolated reports of depression and suicidal ideation, though causal links remain unproven.

GLP-1 medications like semaglutide and tirzepatide are highly effective for weight loss (15-21%), but require careful psychological monitoring. While serious mental health side effects are reported, they are isolated and not causally proven. You should undergo regular mental health check-ins alongside your medical treatment to ensure safety.

Naltrexone/Bupropion combination therapy offers good psychiatric tolerability with only mild, transient anxiety and insomnia, making it a safe alternative for patients concerned about mood stability.

Naltrexone/Bupropion is a well-tolerated weight loss option with a favorable psychiatric profile. While you may experience mild anxiety or insomnia initially, these do not typically progress to serious conditions. It is particularly suitable for patients with emotional eating patterns.

Using GLP-1 RAs post-bariatric surgery can enhance weight loss outcomes and prevent weight regain, whereas using them pre-surgery (neoadjuvant) does not improve surgical outcomes and may slightly reduce weight loss.

If you have had bariatric surgery and are experiencing weight regain, adding a GLP-1 RA can help you lose additional weight. However, taking GLP-1 RAs *before* surgery does not improve surgical results and might slightly reduce the amount of weight lost from the surgery itself.

Pharmacological weight loss agents (GLP-1 agonists, etc.) should be used as adjuncts to lifestyle changes in older adults only after careful case-by-case assessment of sarcopenia risk and limited clinical data.

If lifestyle changes aren't enough, discuss prescription options like GLP-1 agonists with your doctor. Be aware that data for those over 75 is scarce, and these drugs can affect muscle mass, so they must be paired with strength training and protein intake.

Metabolic and bariatric surgery (MBS) provides significantly greater reduction in major adverse cardiovascular events (MACE) and all-cause mortality compared to GLP-1 receptor agonist (GLP-1 RA) therapy in patients with obesity and type 2 diabetes.

If you have obesity and type 2 diabetes, metabolic surgery (like gastric bypass or sleeve gastrectomy) is currently shown to be more effective than GLP-1 medications (like semaglutide or liraglutide) at preventing heart attacks, strokes, and death. While GLP-1 drugs are important for those who cannot have surgery, surgery offers greater long-term cardiovascular protection and more sustained weight loss, though it carries surgical risks and requires lifelong nutritional monitoring.

Interdisciplinary Cognitive-Behavioral Therapy (IT+CBT) effectively supports weight loss and improves quality of life in adults with obesity.

Interdisciplinary Cognitive-Behavioral Therapy (IT+CBT) combines goal setting, impulse control, and problem-solving with cognitive strategies to help patients achieve and maintain weight loss. A small study showed it was superior to health education or physical exercise alone. It requires commitment to therapy sessions.

GLP-1 based therapies (Retatrutide, Ebenatide) cause significant muscle mass loss at higher doses, whereas lower doses or standard GLP-1 agonists preserve muscle mass better.

If you are using high-dose GLP-1 based therapies (like Retatrutide 8-12mg), be aware that you may lose more muscle than with lower doses or standard GLP-1s. This is a trade-off for greater fat loss. Prioritize protein intake and resistance training to protect your muscle mass, especially if you are older.

GLP-1 receptor agonists reduce albuminuria and slow eGFR decline in non-diabetic patients with CKD, particularly those who are obese.

If you have kidney disease and are obese but do not have diabetes, ask your doctor about GLP-1 receptor agonists like semaglutide. Early evidence suggests these medications can significantly reduce albuminuria, a marker of kidney damage, even in non-diabetic patients. However, more research is needed to confirm long-term kidney outcomes in this group.

Preoperative GLP-1 RA therapy (4–8 weeks) reduces liver volume and visceral fat to improve surgical access, provided treatment is discontinued 1 week prior to surgery to mitigate aspiration risk.

If you are scheduled for bariatric surgery and take GLP-1 medications (like Ozempic or Wegovy), you must stop taking them at least one week before your operation. This is not optional; it is a safety requirement to prevent stomach contents from entering your lungs during anesthesia. The goal of this pre-surgery treatment is to shrink your liver and make the surgery technically easier and safer for the surgeon, not necessarily to prevent surgical complications like leaks.

Tirzepatide use in patients at increased risk of cardiovascular events does not increase the risk of serious adverse events or all-cause mortality compared to placebo, but significantly increases the risk of gastrointestinal non-serious adverse events.

If you are at high risk for heart issues, tirzepatide appears safe regarding serious complications like death or hospitalization, but you should expect stomach problems like nausea and diarrhea. These are common but usually not dangerous. Talk to your doctor about starting at a low dose to minimize these effects.

Microbiome-targeted interventions like prebiotics, probiotics, and synbiotics show potential antihypertensive effects, but results are heterogeneous and require larger randomized trials.

While probiotics and prebiotics show promise, they are not yet a proven standalone treatment for hypertension. Focus on a healthy diet and lifestyle first, and consider these supplements as potential adjuncts under medical guidance.

Combining different weight-lowering drugs with complementary mechanisms (e.g., GLP-1 RA with activin receptor antagonist) can enhance weight loss and preserve lean body mass, potentially offering superior cardiovascular protection compared to monotherapy.

For some patients, taking a single weight-loss drug might lead to muscle loss, which isn't ideal for heart health. New combination therapies, such as pairing a GLP-1 drug with a muscle-preserving agent, are being developed to prevent this. These combinations can lead to greater fat loss and better preservation of muscle mass, which is crucial for metabolic health. While these are still emerging, they represent a promising approach for those who struggle with muscle loss on standard treatments.

GLP-1/GIP agonists do not increase overall cancer risk and may reduce incidence of obesity-related cancers (endometrial, ovarian, gastrointestinal) via metabolic improvements, though organ-specific long-term safety remains uncertain.

GLP-1/GIP therapies are not associated with a general increase in cancer risk and may lower risk for obesity-related cancers. However, long-term organ-specific effects are not fully known, so standard cancer screening remains essential.

CJC-1295 and Ipamorelin restore youthful growth hormone secretion patterns by preserving physiological pulsatility, avoiding the adverse effects of continuous exogenous GH administration.

CJC-1295 and Ipamorelin are peptides that stimulate natural growth hormone pulses, potentially reversing age-related muscle loss and fat gain. While they show promise in restoring youthful GH patterns, they are not FDA-approved for anti-aging, and long-term safety data is lacking.

Treatment with tirzepatide is associated with numerically lower impairment in health-related quality of life (HRQoL) domains and work productivity compared to non-pharmacological management or other obesity medications in real-world settings.

If you are managing obesity with tirzepatide, you may experience better daily functioning and work productivity compared to managing it without medication, although individual results vary. This medication is typically taken once weekly alongside diet and exercise. Real-world data suggests these benefits are most pronounced when combined with weight loss.

Orlistat, a pancreatic lipase inhibitor, promotes modest weight loss and improves gut microbiota diversity (increasing Akkermansia and Verrucomicrobia), but its efficacy is significantly lower than GLP-1 agonists.

Orlistat blocks fat absorption, leading to modest weight loss and improved gut bacteria diversity. However, it is significantly less effective than GLP-1 agonists. Side effects like bloating and diarrhea are common if dietary fat is not strictly limited.

Small-molecule oral GLP-1 receptor agonists (e.g., orforglipron) achieve glycemic and weight loss efficacy approaching that of established injectable peptide GLP-1RAs, offering a non-injectable alternative with comparable metabolic benefits.

If you struggle with injections or cold-chain storage, ask your doctor about oral small-molecule GLP-1RAs (like orforglipron). Recent trials show they can lower blood sugar and reduce weight significantly, often approaching the results of injectable drugs. Because they are taken daily, consistency is key, and starting with a low dose to manage stomach side effects is standard practice.

Tirzepatide treatment duration is positively correlated with cumulative cardio-metabolic-kidney (CKM) benefits, with patients persisting on therapy for >1 year achieving significantly greater weight loss, lipid improvements, and hepatic/renal marker reductions compared to short-term users.

If you are using tirzepatide for obesity, sticking with it beyond the first year is critical. The data shows that patients who persist for more than a year lose significantly more weight and see greater improvements in heart, liver, and kidney markers than those who stop early. To maximize these benefits, work with your provider to manage side effects and ensure you have the support and resources to stay on the medication long-term.

Hypertension is associated with urban living, older age, insufficient fruit and vegetable intake, and low physical activity.

Public health initiatives should address these risk factors to manage hypertension.

Diabetes is associated with urban residence, older age, low fruit and vegetable consumption, high salt intake, and low physical activity.

Strategies to reduce diabetes risk should focus on dietary improvements and physical activity.